Organon & Co. (OGN)
NYSE: OGN · IEX Real-Time Price · USD
20.98
+0.01 (0.05%)
At close: Jul 19, 2024, 4:00 PM
21.00
+0.02 (0.10%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Organon & Co. Revenue
Organon & Co. had revenue of $6.35B in the twelve months ending March 31, 2024, with 3.29% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.62B with 5.46% year-over-year growth. In the year 2023, Organon & Co. had annual revenue of $6.26B with 1.44% growth.
Revenue (ttm)
$6.35B
Revenue Growth
+3.29%
P/S Ratio
0.85
Revenue / Employee
$634,700
Employees
10,000
Market Cap
5.40B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6.26B | 89.00M | 1.44% |
| Dec 31, 2022 | 6.17B | -130.00M | -2.06% |
| Dec 31, 2021 | 6.30B | -228.00M | -3.49% |
| Dec 31, 2020 | 6.53B | -1.25B | -16.01% |
| Dec 31, 2019 | 7.78B | -2.00B | -20.46% |
| Dec 31, 2018 | 9.78B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Select Medical Holdings | 6.79B |
| Option Care Health | 4.43B |
| DENTSPLY SIRONA | 3.94B |
| R1 RCM | 2.31B |
| Masimo | 1.98B |
| Merit Medical Systems | 1.28B |
| Doximity | 475.42M |
| Krystal Biotech | 95.95M |
OGN News
- 1 day ago - 20 value stocks with high dividend yields and expected room to raise payouts - Market Watch
- 13 days ago - Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024 - Business Wire
- 2 months ago - CUPE 37 Members Reject City of Calgary Wage Package - Business Wire
- 2 months ago - European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 - Business Wire
- 2 months ago - Organon Announces Pricing of $1.0 Billion Senior Notes Offering - Business Wire
- 2 months ago - Organon Announces Proposed $1.0 Billion Senior Notes Offering - Business Wire
- 2 months ago - Organon Reports Results for the First Quarter Ended March 31, 2024 - Business Wire
- 3 months ago - Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024 - Business Wire